The Disappointing Reality of Crowdfunding Cancer Care
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed. -
Pathologists Need Better Reporting Guidelines for Postneoadjuvant Chemotherapy Specimens
Measuring a tumor’s response to neoadjuvant chemotherapy can be prognostic, providing important clues about a patient’s likely outcome following treatment. -
Cognitive Impairment Following Immunotherapy Treatment May Be Underestimated
As more and more patients undergo immunotherapy treatments, understanding possible side effects on cognitive function is an important research gap. -
The DYSF Gene and Renal Cell Carcinoma: A New Prognostic Biomarker?
There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels.
UROLOGIC CANCERS NEWS
RCC With Isolated Lymph Node Metastases Has Poor Prognosis After Surgery
Hysterectomy Technique Tied to Poorer Uterine Cancer Outcomes
NAC Increases Pathologic Complete Response Rate in High-Risk MIBC
Immunotherapy + Chemo May Improve Outcomes in Metastatic Urothelial Cancer
Adjuvant Sorafenib Does Not Improve Survival in Renal Cell Carcinoma
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
